Activation of HIV-1 from Latent Infection via Synergy of RUNX1 Inhibitor Ro5-3335 and SAHA

PLoS Pathogens

Volumn 10, Issue 3, 2014, Pages

  Klase, Zachary ^a   Yedavalli, Venkat S R K ^a   Houzet, Laurent ^a   Perkins, Molly ^a   Maldarelli, Frank ^b   Brenchley, Jason ^a   Strebel, Klaus ^a   Liu, Paul ^c   Jeang, Kuan Teh ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 1, 3 DIHYDRO 5 (2 PYRROLYL) 2H 1, 4 BENZODIAZEPIN 2 ONE; CD4 ANTIGEN; CORE BINDING FACTOR BETA; GREEN FLUORESCENT PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; VIF PROTEIN; VORINOSTAT;

ARTICLE; BINDING AFFINITY; BINDING SITE; CD4 LYMPHOCYTE COUNT; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN NL4.3); LATENT VIRUS INFECTION; MEMORY CELL; MUTANT; PRIMARY CELL ANALYSIS; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; VIRUS ACTIVATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION; WESTERN BLOTTING;

CCAAT-BINDING FACTOR; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DRUG SYNERGISM; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; MICROSCOPY, CONFOCAL; MUTAGENESIS, SITE-DIRECTED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84897394404     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003997     Document Type: Article

References (52)

1. Greene WC, Peterlin BM, (2002) Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 8: 673-680.
2. Berkhout B, Jeang KT, (1989) trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J Virol 63: 5501-5504.
3. Berkhout B, Silverman RH, Jeang KT, (1989) Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59: 273-282.
4. Yedavalli VS, Benkirane M, Jeang KT, (2003) Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 278: 6404-6410.
5. Brady J, Kashanchi F, (2005) Tat gets the "green" light on transcription initiation. Retrovirology 2: 69.
6. Hakre S, Chavez L, Shirakawa K, Verdin E, (2014) Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 6: 19-24.
7. Karn J, (2011) The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 6: 4-11.
8. Margolis DM, (2010) Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 7: 37-43.
9. Blyth K, Cameron ER, Neil JC, (2005) The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 5: 376-387.
10. Li X, Decker M, Westendorf JJ, (2010) TEThered to Runx: novel binding partners for runx factors. Blood Cells Mol Dis 45: 82-85.
11. Adya N, Stacy T, Speck NA, Liu PP, (1998) The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol 18: 7432-7443.
12. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, et al. (2002) Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111: 621-633.
13. Wong WF, Kohu K, Chiba T, Sato T, Satake M, (2011) Interplay of transcription factors in T-cell differentiation and function: the role of Runx. Immunology 132: 157-164.
14. Wong WF, Kurokawa M, Satake M, Kohu K, (2011) Down-regulation of Runx1 expression by TCR signal involves an autoregulatory mechanism and contributes to IL-2 production. J Biol Chem 286: 11110-11118.
15. Djuretic IM, Cruz-Guilloty F, Rao A, (2009) Regulation of gene expression in peripheral T cells by Runx transcription factors. Adv Immunol 104: 1-23.
16. Bae SC, Lee YH, (2006) Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 366: 58-66.
17. Wee HJ, Voon DC, Bae SC, Ito Y, (2008) PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112: 3777-3787.
18. Taniuchi I, Littman DR, (2004) Epigenetic gene silencing by Runx proteins. Oncogene 23: 4341-4345.
19. Durst KL, Hiebert SW, (2004) Role of RUNX family members in transcriptional repression and gene silencing. Oncogene 23: 4220-4224.
20. Hultquist JF, McDougle RM, Anderson BD, Harris RS (2012) HIV Type 1 Viral Infectivity Factor and the RUNX Transcription Factors Interact with Core Binding Factor beta on Genetically Distinct Surfaces. AIDS Res Hum Retroviruses.
21. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, et al. (2012) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481: 371-375.
22. Zhang W, Du J, Evans SL, Yu Y, Yu XF, (2012) T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481: 376-379.
23. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, et al. (2013) CBFbeta Stabilizes HIV Vif to Counteract APOBEC3 at the Expense of RUNX1 Target Gene Expression. Mol Cell.
24. Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, et al. (2012) Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction. Proc Natl Acad Sci U S A 109: 14592-14597.
25. Levanon D, Groner Y, (2004) Structure and regulated expression of mammalian RUNX genes. Oncogene 23: 4211-4219.
26. Huang G, Shigesada K, Wee HJ, Liu PP, Osato M, et al. (2004) Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood 103: 3200-3207.
27. Yamashita N, Osato M, Huang L, Yanagida M, Kogan SC, et al. (2005) Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol 131: 495-507.
28. Presnell SR, Zhang L, Ramilo CA, Chan HW, Lutz CT, (2006) Functional redundancy of transcription factor-binding sites in the killer cell Ig-like receptor (KIR) gene promoter. Int Immunol 18: 1221-1232.
29. Schug J (2008) Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics Chapter 2: Unit 2 6.
30. Crooks GE, Hon G, Chandonia JM, Brenner SE, (2004) WebLogo: a sequence logo generator. Genome Res 14: 1188-1190.
31. Sorensen KD, Quintanilla-Martinez L, Kunder S, Schmidt J, Pedersen FS, (2004) Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns. J Virol 78: 13216-13231.
32. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
33. Wang J, Reuschel EL, Shackelford JM, Jeang L, Shivers DK, et al. (2011) HIV-1 Vif promotes the G(1)- to S-phase cell-cycle transition. Blood 117: 1260-1269.
34. Challen GA, Goodell MA, (2010) Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells. Exp Hematol 38: 403-416.
35. Wong WF, Nakazato M, Watanabe T, Kohu K, Ogata T, et al. (2010) Over-expression of Runx1 transcription factor impairs the development of thymocytes from the double-negative to double-positive stages. Immunology 130: 243-253.
36. Jordan A, Bisgrove D, Verdin E, (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877.
37. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212.
38. Collins A, Littman DR, Taniuchi I, (2009) RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 9: 106-115.
39. Egawa T, (2009) Runx and ThPOK: a balancing act to regulate thymocyte lineage commitment. J Cell Biochem 107: 1037-1045.
40. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284: 6782-6789.
41. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP, (2009) Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 25: 883-887.
42. Wightman F, Ellenberg P, Churchill M, Lewin SR, (2012) HDAC inhibitors in HIV. Immunol Cell Biol 90: 47-54.
43. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
44. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
45. Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, et al. (1991) Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254: 1799-1802.
46. Mei HY, Mack DP, Galan AA, Halim NS, Heldsinger A, et al. (1997) Discovery of selective, small-molecule inhibitors of RNA complexes-I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. Bioorg Med Chem 5: 1173-1184.
47. Dunne AL, Siregar H, Mills J, Crowe SM, (1994) HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429. J Leukoc Biol 56: 369-373.
48. Cupelli LA, Hsu MC, (1995) The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol 69: 2640-2643.
49. Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, et al. (1995) A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis 172: 1246-1252.
50. Cohen MM Jr, (2009) Perspectives on RUNX genes: an update. Am J Med Genet A 149A: 2629-2646.
51. Collins A, Hewitt SL, Chaumeil J, Sellars M, Micsinai M,et al. RUNX Transcription Factor-Mediated Association of Cd4 and Cd8 Enables Coordinate Gene Regulation. Immunity 34: 303-314.
52. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, et al. (2009) BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10: R130.